Introduction
CD56, a natural killer (NK) cell marker also called neuronal cell adhesion molecule, identifies a cell subset comprising 10-15% of peripheral blood (PB) mononuclear cells. 1, 2 No B cell non-Hodgkin's lymphoma (NHL) displays such a molecule, while about 20% of non-B NHL are CD56 + .
3-5 Among CD56
+ NHL patients, the subgroup displaying CD3 and TcR␣␤ or ␥␦ clearly belongs to T cell malignancies. Another subgroup, lacking CD3 and TcR, resembles 'pure' NK neoplasms; nevertheless, these cases can be further split into two subsets: those displaying clonally rearranged TcR genes, called NK-like T cell neoplasms, and those showing a germline configuration of TcR genes, classified as 'pure' NK malignancies. [6] [7] [8] [9] In this paper, we describe two novel cell lines, DERL-2 and DERL-7, established from PB and bone marrow (BM), respectively, of a patient with an unusual type of hepatosplenic ␥␦ T cell lymphoma, 10 T cell-restricted antigens. Both populations rearranged the TcR genes with an identical pattern. The interest of this case relied on the cell type-related clinical picture: it was indolent when TcR␥␦ + cell population was predominant, dramatic when a marked infiltration of BM by TcR − cells occurred.
11
The two cell lines established, both CD56 + , showed a distinct phenotype, corresponding to the two different components and phases of the disease: DERL-2 was TcR␥␦ + , while DERL-7 was TcR␥␦ − . Here we present the phenotypic, genetic and functional properties of these two cell lines. We followed the guidelines for characterization and publication of human malignant hematopoietic cell lines previously published in this journal.
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Materials and methods
Case history
This patient has already been reported in details elsewhere; 11 the history is briefly summarized below. In February 1995, a 30-year-old male was admitted to the Hematology Department with fever, anemia and lymphocytosis. Physical examination showed liver and spleen enlargement and no palpable lymph nodes. Blood counts showed WBC 15.4 × 10 9 /l with 58% atypical lymphoid cells. BM examination revealed erythroid hyperplasia and minimal (7%) atypical lymphoid cell infiltration. Flow cytometry immunotyping showed two cell populations, both CD2 A fine needle aspirate from the spleen suggested large cell NHL. Following a period of treatment with prednisone (1 mg/kg), the MACOP-B scheme was started, and interrupted after 4 weeks because of disease progression (May 1995) . A second choice polychemotherapy (ifosfamide, cytarabine, high-dose methotrexate and methylprednisolone) was initially effective but after a few weeks a bone marrow aspirate showed complete replacement by a lymphoid blast cell population with striking prevalence of CD3 − , TCR␥␦ 
Cell culture
To obtain multiple cell lines from a single patient, we followed a strategy previously described, based upon maintaining in vitro a large number of split subcultures. 13 Briefly, 6 /ml in 5 ml of medium consisting of RPMI-1640 (Seromed, Biochrom KG, Berlin, Germany) with 20% fetal bovine serum (Seromed, Biochrom KG), 2 mM L-glutamine (Gibco BRL Life Technologies, Paisley, UK), antibiotics and 40 ng/ml recombinant human interleukin-2 (IL-2; Proleukin, EuroCetus, Amsterdam, The Netherlands). All cultures were incubated at 37°C with 5% CO 2 ; during the first 6 weeks, fresh culture media was added at 7-day intervals, replacing half of the medium each time. When the cells began to proliferate, they were subcultured in new flasks. Cell count and viability were assessed by flow cytometry analysis. A test for mycoplasma (Boerhinger Mannheim, Mannheim, Germany) was performed at regular intervals to exclude culture contaminations.
Morphology, cytochemistry and cell marker analysis
Cytospin preparations of DERL-2 and DERL-7 cells were stained with May-Grü nwald-Giemsa and morphology was evaluated under a light microscope. In addition, cell preparations were tested for the myeloperoxidase (MPO) and periodic acid-Schiff (PAS) cytochemical staining.
Cell surface antigens were tested by flow cytometry (FCM) with a FACScalibur (Becton Dickinson), as described. 13 Cell viability was routinely assessed by analysis of light scatter properties. Living cells were also scored daily under a phase contrast microscope.
The membrane expression of differentiation antigens was investigated with a panel of monoclonal antibodies (MoAb) directly coupled with fluorescein (FITC) or phycoerythrin (PE), 
Authentication of cell lines
The identity of DERL cell lines was checked against a bone marrow cell sample withdrawn from the patient during the progression phase using the DNA fingerprint technique.
14 The following nine highly polymorphic short tandem repeat (STR) loci were tested by three multiplex PCR reactions: D3S1358 (on chromosome 3), vWA (on chromosome 12p12), FGA (on chromosome 4q28), D8S1179 (on chromosome 8), D21S11 (on chromosome 21), D18S51 (on chromosome 18q21), D5S518 (on chromosome 5), D13S317 (on chromosome 13), D7S820 (on chromosome 7). The multiplex PCR reaction conditions and primers were chosen according to previous description, 15 and the size of amplified products was determined by a DNA capillary electrophoresis apparatus ABI 310 Genetic Analyzer (PE Biosystems Italia, Monza, Italy) at a single base definition.
Karyotype and TcR rearrangement analysis
Chromosome analysis was performed as follows: the cultured cells were treated with 75 mM hypotonic KCL solution for 30 min at 37°C and then fixed with methanol/acetate (3:1) solution. The chromosomes were banded by tripsin-Giemsa staining. 16, 17 Mononuclear cells from BM and PB withdrawn at diagnosis, along with the cell lines, were analyzed for TcR gene rearrangements by Southern blotting. High molecular weight genomic DNA was extracted by the phenol/chloroform method. 18 Aliquots of 15 g of genomic DNA were digested with 50 U of restriction enzymes (New England Biolabs, Beverly, MA, USA), electrophoresed on 0.8% agar gel, and blotted on positively charged nylon membranes (Highland Nplus, Americium, UK). Following transfer, DNA was immobilized on to the membrane by incubation at 60°C in a vacuum oven and hybridized to 50 ng of one of three radioactively labeled genomic probes. Rearrangement of the gene encoding the ␤ chain of TcR were studied by the CB probe, a 1.1-kb EcoRI-HindIII DNA fragment, recognizing both C␤1 and C␤2 sequences. 19 Rearrangements of the genes encoding the ␥ and ␦ chain of the TcR were studied by J␥ 1.3 and J␦ 1 probes, respectively. The J␥ 1.3 probe, a 0.8-Kb EcoRI-HindIII genomic DNA fragment, recognizing both J␥ 1.3 and J␥ 2.3 gene segments, detects all rearrangements of TcR-␥ gene in EcoRI restriction enzyme digests. 20 The J␦1, a 0.5-kb SacI-EcoRI genomic DNA fragment, which recognizes a J␦1 gene segment, detects TcR-␦ gene rearrangements and deletion. 21 
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Assays for lymphotropic viral infections
The infection by the most common lymphotropic viruses such as Epstein-Barr virus (EBV), human T-lymphotropic virus type I and II (HTLV-I/-II), and human herpes virus 8 (HHV8), was tested by PCR amplification of proviral genomes in DNA extracted from the two cell lines.
In the case of EBV, the target of amplification assay was the internal repetitive fragment of EBV proviral genome and the assays were carried out using a two-step reaction: in the first, 200 ng of genomic DNA was amplified using the primers 1 and 2 in Table 1 . In the second step, 1/50 of the amplification product was re-amplified using the 'nested' primers 3 and 4 of Table 1 . 22 In each of the reactions, the reaction mixture contained 50 mmol/l KCl, 10 mmol/l Tris-HCl pH 8. HHV8 infection was tested by PCR using a single-step reaction assay and a couple of primers designed in the viral orf 26 (primers 5 and 6 of Table 1) . 23, 24 The reaction mixture was the same as in the EBV amplification. The amplification reaction consisted of 45 cycles of amplification (1 min 95°C, 30 s 60°C, 30 s 72°C). In this case, the positive control of HHV8 amplification was DNA from the BCBL-1 cell line.
The infection by HTLV type I and II was tested using a single couple of primers (primers 7 and 8 in Table 1 ) designed in the group-specific sequence of proviral tax gene which is common to the two types of viral strains. 25 In this assay, the PCR reaction consisted of 45 cycles of amplification (1 min 95°C, 30 s 55°C, 30 s 72°C). The positive control of HTLV amplification was a DNA sample from HUT-102 cell line.
Proliferation assay
Prior to examining the growth response of the cell lines to growth factors (GF), the cells were starved for 20 h in medium without any GF. Then they were washed, viable cells were quantified by FCM and cultured for 7 days at 37°C in a Leukemia humidified 5% CO 2 atmosphere, at a concentration of 2.5-5 × 10 5 /ml in the presence of GF. Control cultures without GF were also established. The panel of recombinant human GFs was composed by interleukin-2 (IL-2, Proleukin, EuroCetus, Amsterdam, The Netherlands), stem cell factor (SCF, Biosource International, Camarillo, CA, USA), granulocytemacrophage colony-stimulating factor (GM-CSF, ScheringPlough, Innishannon, Eire), interleukin-4 (IL-4, Biosource International), interleukin-7 (IL-7, Biosource International), interleukin-12 (IL-12, Sigma Biosciences, St Louis, MO, USA), interleukin-6 (IL-6, Biosource International), interferon-gamma (IFN-␥, Pharmingen). Dose-response curves were determined by culturing the cells for 7 days with: IL-2 0.8 ng/ml (10 U/ml) to 80 ng/ml (1000 U/ml); SCF 2.5 ng/ml to 500 ng/ml; GM-CSF 1.5 ng/ml to 1500 ng/ml; IL-4 0.5 ng/ml (5 U/ml) to 50 ng/ml (500 U/ml); IL-7 0.01 ng/ml (1 U/ml) to 1 ng/ml (100 U/ml); IL-12 0.5 ng/ml (5 U/ml) to 50 ng/ml (500 U/ml); IL-6 10 ng/ml to 1000 ng/ml; IFN-␥ 0.5 ng/ml (10 U/ml) to 50 ng/ml (1000 U/ml). Intermediate concentrations of IL-4, IL-7, IL-12, IL-6, and IFN-␥ were also used in combinations with various concentrations of IL-2, in order to evidence synergistic effects on cell growth. Moreover, 250 ng/ml SCF was utilized in combination with different doses of IL-2. The proliferation was assayed by counting in triplicate cells before and after treatment with the various cytokines; counts were performed by FCM, using a syringe cytometer able to effect absolute count (Cytoron Absolute, Ortho Clinical Diagnostics). 26 Cytotoxicity assay K562 cell line was used as target cell. These cells were maintained in continuous suspension cultures in RPMI 1640 plus 10% FBS, 2 mM L-glutamine and antibiotics. A FCM method was used to evaluate DERL-2 and DERL-7 cell line cytotoxicity. 27 As a positive control, PB mononuclear cells were isolated on a Ficoll-Paque gradient from buffy coats obtained from normal donors. The mononuclear cells were washed twice with RPMI 1640 plus 10% FBS and deprived of monocytes by adhesion to plastic flask walls for 30 min at 37°C in a 5% CO 2 atmosphere. Normal mononuclear cells or DERL cell lines were suspended in the working solution (0.5 g/ml propidium iodide in RPMI 1640 plus 20% FBS, 2 mM L-glutamine and 40 ng/ml rhIL-2), mixed and incubated for 12 h at 37°C with K562 at various effector:target (E:T) ratios in a final volume of 1 ml/well in a 24-well plate. Then the samples were harvested, spun at room temperature for 7 min at 250 g and stained with MoAbs anti-CD14 (in PBMC control assays, to identify and gate-out monocytes) and anti-CD7 (in DERL-2 and DERL-7 assays, to identify and gate-in effector cells). Target cells were preliminarily gated using the forward vs 90°s catter cytogram; then CD14 or CD7 were used to exclude unwanted effector cell populations. Cytotoxicity was expressed as the % of PI-positive target cells among the target cell cluster.
Results
Establishment of cell lines
Approximately 6 weeks after the beginning of the cultures (May 1995), the cells began to proliferate and the floating cell population was subcultured in new flasks. Within a few weeks, a series of 14 subcultures were obtained. Three months later, two subcultures began to grow vigorously, and two cell lines, DERL-2 (from PB) and DERL-7 (from BM) were judged to be established. The later passages showed doubling times of 72 h at a cell density of 1 × 10 6 /ml (0.5 × 10 6 -3 × 10 6 /ml). Both cell lines were in continuous culture until May 1996, when aliquots were cryopreserved.
The cryopreserved cell lines were routinely thawed and cultured for further characterization, and all aliquots showed stable doubling time of 72 h.
Morphology
Phase contrast microscopy revealed in both lines cell size homogeneity and a clear-cut tendency to form aggregates.
Results of morphological studies with May-Grü nwaldGiemsa-stained cytospin preparations are shown in Figure 1 . DERL-2 cells were round with a high nucleo-cytoplasmic ratio. The nuclei were irregular in shape, the chromatin pattern was granular (sometimes showing high degree of condensation). One prominent nucleolus was usually present along with two or three of smaller size. The cytoplasm was moderately basophilic, agranular with variable prominent vacuolization and a visible Golgi zone. DERL-7 morphology was similar, although a few differences could be noted: the cells exhibited an eccentric nucleus with clumped chromatin and visible nucleolus. The cytoplasm was strongly basophilic and a less prominent Golgi zone was observed.
A cytochemical characterization showed myeloperoxidase and PAS negativity of both cell lines.
Immunophenotype
Cell lines were established from PB and BM mononuclear cells withdrawn during the progression phase, in May 1995. At that time, BM was replaced by CD2
+ cells accompanied by 2-3% residual population of CD3 + TCR␥␦ cells. 11 The surface marker analysis of DERL-2 and DERL-7 cells is reported in Table 2 . Both cell lines were clearly positive (Ͼ30% positive cells) for CD2, CD7, CD56, CD158b, CD26, CD69, CD95, CD11a, CD54, CD59, CD117, CD45, CD45RA and cytoplasmic
Figure 1
Microphotographs of DERL-2 and DERL-7. DERL-2 (a) cells showed a granular chromatin pattern. One prominent nucleolus was usually present along with two or three of smaller size. The cytoplasm showed a visible Golgi zone. DERL-7 (b) exhibited an eccentric nucleus with clumped chromatin and visible nucleolus. A less prominent Golgi zone was observed.
CD3⑀. Searching for differences between the two cell lines, we found that DERL-2 was also positive for surface CD3, CD8, TCR␥␦, NKB1, CD52, CD66abce, CD33 and CD45R0, while DERL-7 was negative for the above markers and brightly stained with the CD158a MoAb. CD117/c-kit, although expressed by both cell lines, displayed higher percentage of positive cells (Table 2 ) and brighter fluorescence intensity (data not shown) on DERL-7.
CD122 and CD132 were expressed, in both cell lines, on a percentage of cells comprised between 10 and 20%.
Cytogenetic analysis
Forty-five metaphases were analyzed (25 for DERL-2 and 20 for DERL-7). DERL-2 cell line showed a near-diploid karyotype: 46XY 5q+,i(7) (10 metaphases)/46 XY 5q+, +i(7), −10 (five metaphases); random abnormalities (10 metaphases). DERL-7 cell line had a more complex karyotype in the 20 metaphases analyzed: 46 XY −4, +i(7) (nine metaphases)/47 XY −4, +i(7), +11 (four metaphases)/46 XY −4, +i(7), + der (7) Two novel cell lines from a patient with CD56 ؉ lymphoma R Di Noto et al 1645 Table 2 Immunophenotypic analysis of the two novel cell lines 
Authentication of cell lines
The fingerprint analysis of DNA extracted from DERL cell lines and bone marrow mononuclear cells withdrawn from the patient during the progression phase showed that eight out the nine STR loci tested were informative, ie gave amplification of two alleles with different length. The results (see Table 3 ) showed a complete correspondence of the allele detected at the informative loci between cell line and patient cells thus proving the direct derivation of DERL lines from those cells.
Detection of TCR rearrangements
The two cell lines showed identical results ( Figures 3 and 4 ). Southern analysis of the genes encoding the ␤ chain of T cell receptor (TcR) is shown in Figure 3 . The presence of two rearranged bands with the HindIII digest, along with the 
Lymphotropic viral infections
The presence of integrated genomes of EBV, HTLV-I/-II, and HHV-8, the lymphotropic viruses most commonly found in human lymphoid malignancy was excluded in both cell lines by PCR analysis, thus excluding the infection by such viruses both in cell lines and in leukemic blasts from which the lines were obtained.
Effect of growth factors on DERL-2 and DERL-7 proliferation
The effects of selected GFs on the proliferation of these cells were assessed by counting viable cells before and after treatment with the various cytokines. The values were calculated in comparison to the growth level without GFs and are averages of triplicates. GM-CSF, IL-4, IL-6, IL-7, IL-12 and IFN␥ had no significant effect on cell growth in either DERL-2 or DERL-7; IL2 (40 ng/ml) and SCF (250 ng/ml) were the only cytokines active on both cell lines. Dose-response curves showed that SCF supported the growth of both cell lines, although the preferential target was DERL-2 (four-fold basal level, Figure 5a ). SCF stimulated DERL-2 and DERL-7 in a concentration-dependent manner with the maximal stimulation at 250 ng/ml (Figure 5a and b) . The IL-2-dependent growth of DERL-2 and DERL-7 was demonstrated by growth curves in the presence of various concentrations of IL-2; the maximal stimulation was obtained in both cases at 80 ng/ml (Figure 5c and d). Cell growth induced on DERL-7 cell was more vigorous as compared to DERL-2: 0.8 ng/ml were able to promote cell duplication within 7 days, while 80 ng/ml induced an eight-fold augmentation of the cell number (Figure 5d ). We studied the effects of the simultaneous exposure to the two growth factors on the growth of DERL-2 and DERL-7 (Figure 5e and f). As shown, in both cell lines SCF, used at a concentration of 250 ng/ml, displayed a synergistic effect when added to increasing concentration of IL-2. Three different assays gave identical results. Both SCF and IL2 were able to down-modulate the membrane expression of c-kit, as assessed by in vitro induction experiments and flow cytometry (data not shown).
When the cells were cultured in the absence of externally added growth factors, we observed a growth arrest with sustained viability; apoptosis involved a small percentage of cells and occurred after 4 days of culture.
Cytotoxic activity
Natural killer activity was not detected in the DERL-2 and DERL-7 cell lines, in comparison with the natural killer activity of normal PBL.
Discussion
In the present study, we describe two novel CD56
+ cell lines, DERL-2 and DERL-7, established from the peripheral blood and bone marrow, respectively, of a patient with hepatosplenic ␥␦ T cell lymphoma. This patient was unique in that he showed in different phases of the disease the alternate predominance of two distinct populations of cells: TCR ␥␦ + cells at diagnosis and TCR␥␦ − cells during relapse. 11 Although the establishment process was started from cells of a bone marrow sample obtained during the disease progression, when both BM and PB contained 97% of TCR␥␦ − cells and only 2-3% of residual TCR␥␦ + cells, we were able to establish two IL2-dependent cell lines, corresponding to the two components of the disease. This study confirms our previous observation indicating the possibility of successfully establishing more than one cell line from a single patient, thus obtaining a multisided cellular model. 13 This is the first report concerning the Leukemia establishment of two cell lines with strikingly divergent phenotype from a single case of hepatosplenic ␥␦ T cell lymphoma. 28, 29 The features of our cell lines seem to recapitulate recent information about the existence of a common progenitor for T and NK cells. 1 The common ancestor of these two cell lines probably resides at a cross-point before T cell and NK cell terminal differentiation.
In order to precisely assess the differentiation stage of the two cell lines, we evaluated a large number of cell markers, including T, NK, myeloid and B cell associated molecules. DERL-2 and DERL-7 expressed a series of molecules shared by normal T and NK cells. First of all, both cell lines showed CD7 and CD2, two molecules expressed on bipotential T/NK progenitors, which precede TcR rearrangements.
1 These molecules are expressed by T cells, as well as by NK cells, from progenitors to mature cells. 1 Secondly, both cell lines expressed two activation molecules also described as T and NK cell associated: CD69 and CD26. The former is inducible on immature thymocytes and on activated T and NK cells and is constitutively expressed by mature thymocytes; 30 the latter (also called DPP IV) is expressed on subsets of T cells, as well as on activated NK cells. 31 A previously published study on aggressive hepatosplenic T cell lymphoma demonstrated the expression of CD26 with preserved DPP IV activity, and suggested the possibility that this molecule might be a participant in the pathogenic mechanisms utilized by the neoplastic cells. 32 Both cell lines expressed the adhesion system LFA-1 (CD11a)/ICAM-1(CD54). No difference in the expression of these two adhesion molecules was observed when comparing the two cell lines. On immunophenotypic grounds, this was not a surprising finding, given the nature of broadly distributed non-lineage antigens of CD11a and CD54. From a functional point of view, the presence of these two reciprocal counterreceptors may account for the clear-cut tendency to form aggregates in culture. Finally, both cell lines expressed the NK receptor CD158b, a molecule prevalently expressed by NK cells, but also capable on T cells of altering the strength of T cell responses at a given antigen dose and of controlling immune responses to target cells with unbalanced levels of class I MHC expression. 33 
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؉ lymphoma R Di Noto et al Searching for differences between the two cell lines, we found that in DERL-2, T cell specificities (CD3 and TCR␥␦) were accompanied by the coexpression of the CD45 isoforms RA and R0, 1 CD8 and NKB1, a 70 kDa glycoprotein expressed on a subset of NK and T cells, 34 whose interaction with specific HLA-B antigen on target cells inhibits cell-mediated cytotoxicity, possibly by delivering negative signals. By contrast, DERL-7 was CD45R0, CD8 and NKB1 negative and strongly expressed the receptor for HLA-C alleles CD158a. 35 The divergent expression of NKB1 and CD158a molecules in these two cell lines will enable additional studies concerning the biological function and balance of NK receptors on NK-like T cells.
Difference in CD117 expression is interesting although it is not able to support different cell maturation stage. In fact both the cells are TdT-negative and are to be considered mature TcR rearranged T cell. 36 Both cell lines express cytoplasmic CD3, as detected by the antibody IOT-3/UCHT-1, directed to CD3⑀ protein. This finding was not unexpected, since it has been demonstrated that, although resting mature NK cells do not express significant levels of cyCD3 protein (except for CD3), CD3⑀ mRNA and protein are rapidly up-regulated in these cells after activation in presence of IL2.
1 Both cell lines express very low, but distinct levels of IL-2 receptor chains CD122 and CD132. This finding may explain clear-cut IL-2 dependency of both DERL-2 and DERL-7.
DERL-2 cell line showed near-diploid karyotype, with i(7q) in all metaphases studied, 5q
+ and loss of one chromosome 10. DERL-7 had i(7q), accompanied by the loss of one chromosome 10 and of one chromosome 4. Isochromosome 7q is one of the most commonly occurring isochromosomes in neoplasia and it has been proposed that this chromosome abnormality may play a pivotal role in the pathogenesis of hepatosplenic ␥␦ T cell lymphoma. 37, 38 According to Ansell et al, 39 this cytogenetic abnormality in hepatosplenic ␥␦ T cell lymphoma could indicate a worse prognosis. Our observation that clonal i(7q) was present in both cell lines further supports the hypothesis of a common progenitor for DERL-2 and DERL-7 and further indicates the neoplastic nature of both cell lines. We also found chromosome 10 deletion in both cell lines. In a survey of cytogenetic literature, we found that chromosome 10 abnormalities are present in NK/T cell lymphoma leukemia with sufficient regularity to be considered recurrent events. 40 In order to obtain unequivocal evidence to demonstrate that our cell lines, DERL-2 and DERL-7, are T cell-derived and share a common ancestor with the original tumor cells, we showed that the T cell receptor genes were rearranged and that identical rearranged bands were observed in patient's leukemic cells and the resulting cell lines. A likely interpretation is that the disease originated from the neoplastic transformation of a bipotential T-NK progenitor cell and that TcR rearrangement occurs just before, or at the moment of divergence between NK and T differentiation. This progenitor cell still retained the ability to start the differentiation and maturation program along a T or NK pathway, and gave rise to two subclones with divergent phenotype and different biological properties.
Our cell lines were clearly IL2-dependent since the early phases of their establishing process. SCF proved to be a suitable alternative to sustain DERL-2 and DERL-7 growth. From our experiments, it appears that IL2 is a dominant cytokine for DERL-7, while SCF is the preferred GF for DERL-2. It should be noted that we demonstrated that IL2 and SCF acted synergistically on these cell lines. IL2 and SCF were recently shown to act synergistically in promoting the proliferation of CD56 bright human peripheral blood NK cells as well as of certain T cells. 36, 41 Moreover, SCF has been demonstrated to be capable of enhancing IL2-mediated expansion of murine NK cells in vivo. [42] [43] [44] However, in these settings it is not clear whether the injected cytokines directly influenced NK cells or acted indirectly by modifying the stromal cell microenvironment. In normal NK cells, synergy was reported to be mediated by induction of the high affinity IL-2 receptor. The availability of a stable two-sided model enabling the study of such a concerted action could be an important advantage. SCF and IL2 may represent in the future a therapeutic strategy for NK cell expansion in order to enhance the immune surveillance against malignant transformation.
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To date, only a few permanent NK-like cell lines have been published. 28, [45] [46] [47] Our two novel cell lines have features not previously described for other cell lines, potentially providing suitable models to study new aspects of T/NK biology.
Availability of the cell lines
DERL-2 and DERL-7 cell lines will be made available to outside investigators upon request to the first author. 
